Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $2.15 per share in its upcoming report, which indicates a year-over-year increase of 6.4%. Revenues are expected to be ...

If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, ...

Retail buzz spiked around Gilead Sciences Inc. after the biotech firm on Sunday revealed new data showing that its cancer ...

Gilead (GILD) stock is in focus as the company halts a Phase 1 trial for its long-acting HIV injectable GS-1219, spotlighting ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for ...

(Yicai) Oct. 27 -- Gilead Sciences has benefited from China's accelerated regulatory reforms in granting market access for innovative drugs, with the country's pilot zones enabling near-simultaneous ...

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

The Boys and Girls Club of County was one of eight clubs nationwide awarded funding to expand its science, technology, engineering and mathematics (STEM) programming. Timika Thrasher, the CEO of the ...